The chairperson and board member for Sun Pharmaceutical Industries Ltd., Israel Makov will be retiring after his term ends on August 29, 2022. This was announced by the company in a Wednesday statement. Makov's replacement has yet to be announced by the company.
Makov has led the Sun Pharma board over the past ten years. In 2012, he was elected to the board as a member of the company's chairperson. Under his leadership, the pharmaceutical company has grown its presence beyond India and the US to more than 100+ markets. It is now the fourth-largest specialty-generic pharmaceutical company in the globe.
"It was an honor to have been a part of the exciting journey Sun Pharma made in becoming a global leader in the pharmaceutical industry. Makov stated that he enjoyed working with Sun Pharma's talented executives and how they led the transformation of the company.
Sun Pharma stated that the company's turnover grew from $1.7 billion up to $5 billion over the past decade. Makov, a former president of Teva Pharmaceutical Industries and CEO, also supervised Ranbaxy's acquisition in 2014. This move strengthened the company's position within the pharmaceutical industry. Makov was also the former chairperson at Given Imaging, which developed and provided capsule endoscopy. Netafim developed smart irrigation systems. Makov also co-founded Israel's first biotech firm Interpharm. It went public in the US.